Altimmune prices $75M registered direct offering

Altimmune (ALT) “intends to use the net proceeds to fund preparation for its upcoming Phase 3 trial in metabolic dysfunction-associated steatohepatitis as well as for working capital and general corporate purposes. Pemvidutide is a balanced glucagon/GLP-1 dual agonist and has the potential to be a highly differentiated therapy for patients with MASH, as demonstrated by the recently-announced Phase 2b 48-week topline data and the Breakthrough Therapy Designation from the U.S. FDA. The Company continues to focus on delivering meaningful impact for patients and long-term value for shareholders. Titan Partners, a division of American Capital Partners, is acting as the sole placement agent for the offering.”